NCT02412982View on ClinicalTrials.gov

Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Traumatic InjuryVenous Thromboembolism
Interventions
DRUG

Enoxaparin 40 mg q12h

Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.

DRUG

Enoxaparin 30 mg q8h

Patients receive enoxaparin 30 mg every 8 hours.

Trial Locations (1)

45216

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

United States Air Force

FED

lead

University of Cincinnati

OTHER

NCT02412982 - Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients | Biotech Hunter | Biotech Hunter